Chemours Company (The) (NYSE:CC) – Research analysts at Jefferies Group cut their Q3 2017 earnings per share (EPS) estimates for shares of Chemours Company (The) in a research report issued to clients and investors on Wednesday. Jefferies Group analyst L. Alexander now forecasts that the specialty chemicals company will post earnings of $0.97 per share for the quarter, down from their prior estimate of $1.03. Jefferies Group currently has a “Buy” rating and a $60.00 price target on the stock. Jefferies Group also issued estimates for Chemours Company (The)’s Q4 2017 earnings at $0.96 EPS, FY2017 earnings at $3.55 EPS and FY2020 earnings at $5.20 EPS.

Chemours Company (The) (NYSE:CC) last announced its quarterly earnings data on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, beating the Zacks’ consensus estimate of $0.85 by $0.02. Chemours Company (The) had a net margin of 4.96% and a return on equity of 122.97%. The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm posted $0.27 EPS. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. COPYRIGHT VIOLATION NOTICE: “Jefferies Group Research Analysts Decrease Earnings Estimates for Chemours Company (The) (NYSE:CC)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/07/jefferies-group-research-analysts-decrease-earnings-estimates-for-chemours-company-the-nysecc.html.

CC has been the topic of a number of other reports. Citigroup Inc. reaffirmed a “neutral” rating and set a $40.00 price target (up from $34.00) on shares of Chemours Company (The) in a research report on Friday, April 14th. ValuEngine raised shares of Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Friday, June 2nd. J P Morgan Chase & Co raised shares of Chemours Company (The) from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $39.00 to $50.00 in a research report on Friday, May 12th. BidaskClub cut shares of Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Saturday, June 17th. Finally, Zacks Investment Research raised shares of Chemours Company (The) from a “hold” rating to a “strong-buy” rating and set a $51.00 price target on the stock in a research report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $44.50.

Shares of Chemours Company (CC) opened at 49.31 on Monday. Chemours Company has a 12 month low of $8.86 and a 12 month high of $49.67. The firm has a 50 day moving average of $41.37 and a 200-day moving average of $37.03. The stock has a market capitalization of $9.13 billion, a P/E ratio of 32.25 and a beta of 3.63.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in Chemours Company (The) by 51.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 491,439 shares of the specialty chemicals company’s stock valued at $10,856,000 after buying an additional 167,183 shares in the last quarter. Teachers Advisors LLC boosted its stake in Chemours Company (The) by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 309,248 shares of the specialty chemicals company’s stock valued at $6,831,000 after buying an additional 7,432 shares in the last quarter. Charter Trust Co. bought a new stake in Chemours Company (The) during the first quarter valued at about $215,000. First American Bank bought a new stake in Chemours Company (The) during the first quarter valued at about $262,000. Finally, Cypress Capital Management LLC WY boosted its stake in Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock valued at $162,000 after buying an additional 80 shares in the last quarter. 75.21% of the stock is currently owned by institutional investors and hedge funds.

In other news, VP Erich Parker sold 4,908 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $45.53, for a total transaction of $223,461.24. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Paul Kirsch sold 19,036 shares of the business’s stock in a transaction on Monday, June 5th. The stock was sold at an average price of $41.42, for a total transaction of $788,471.12. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

The company also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 17th will be given a dividend of $0.03 per share. The ex-dividend date is Tuesday, August 15th. This represents a $0.12 dividend on an annualized basis and a dividend yield of 0.24%. Chemours Company (The)’s payout ratio is currently 8.11%.

About Chemours Company (The)

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Earnings History and Estimates for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.